Log in to your Inderes Free account to see all free content on this page.
Probi
347
SEK
0 %
PROB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
0%
+24.82%
+37.15%
+62.15%
+70.94%
+75.7%
-21.49%
+50.54%
+3,134.72%
www.probi.com/investor-relations
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Revenue
627.69M
EBIT %
1.8 %
P/E
234.46
Dividend yield-%
0.37 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
PROB
Daily low / high price
347 / 349
SEK
Market cap
3.95B SEK
Turnover
266.93K SEK
Volume
768
Latest videos
Financial calendar
Annual report
28.01.2025
Interim report
23.04.2025
General meeting
06.05.2025
Interim report
17.07.2025
Interim report
23.10.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Symrise | 69.7 % | 69.7 % |
Fjärde AP-fonden | 9.3 % | 9.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Probi CFO departure
Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio